Lipid Sciences, Inc.' Atherosclerosis Regression Data Presented at EuroPCR 2008 Congress

PLEASANTON, CA--(Marketwire - May 14, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) -- Dr. Ron Waksman, Associate Director, Division of Cardiology, Washington Hospital Center, Washington, D.C., presented preliminary results and new clinical safety data supporting Lipid Sciences' HDL Selective Delipidation technology during a Late-Breaking Trials session at the EuroPCR 2008 Congress in Barcelona, Spain, yesterday. Dr. Waksman, an internationally-recognized interventional cardiologist, was the principal investigator for the Company's clinical trial, "A Randomized Single-Blind Placebo-Controlled Study to Evaluate the Safety of Lipid Sciences' PDS-2 in Subjects with Acute Coronary Syndrome (ACS)."